Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.52 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30225124 | 1.00 | NAPRT (0.59) | NAPRTALDH1A1CYP1A2CYP3A4CYP2C9 | |
| Hydrochloric Acid SCHEMBL30543987 | 0.98 | NAPRT (0.57) | NAPRTALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL15885763 | 0.88 | NAPRT (0.53) | NAPRTALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL6604387 | 0.87 | NAPRT (0.56) | NAPRTALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL232040 | 0.85 | NAPRT (0.44) | NAPRTALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL27868362 | 0.84 | L3MBTL1 (0.61) | NAPRTALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL9709514 | 0.84 | EPHX2 (0.52) | ALDH1A1CYP1A2CYP3A4CYP19A1KMT2A | |
| SCHEMBL7863128 | 0.84 | CTDSP1 (0.56) | NAPRTALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL3957320 | 0.84 | CYP4F2 (0.55) | ALDH1A1TSHRKMT2A | |
| SCHEMBL29001632 | 0.83 | MKNK1 (0.54) | CYP1A2CYP3A4CYP2C9CYP19A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 632 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4314945-B1 | ELECTROCHROMIC ELEMENT, ELECTROCHROMIC DISPLAY DEVICE, ELECTROCHROMIC LIGHT-CONTROLLING DEVICE, AND ELECTROLYTE COMPOSITION | RICOH CO LTD (JP) | 2025-12-17 | — | — | EP | claimed |
| US-5939568-A | Accelerated catalysis of olefinic epoxidations | THE SCRIPPS RESEARCH INSTITUTE (US) | 1999-08-17 | — | — | US | claimed |
| WO-1998033786-A9 | ACCELERATED CATALYSIS OF OLEFINIC EPOXIDATIONS | — | 1998-12-30 | — | — | WO | claimed |
| WO-1998033786-A1 | ACCELERATED CATALYSIS OF OLEFINIC EPOXIDATIONS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1998-08-06 | — | — | WO | claimed |
| US-12630742-B2 | Polishing composition using polishing particles containing basic substance and having high water affinity | NISSAN CHEMICAL CORPORATION (JP) | 2026-05-19 | — | — | US | disclosed |
| US-20260117105-A1 | POLISHING COMPOSITION HAVING EXCELLENT STORAGE STABILITY AND METHOD FOR PRODUCING SAME | NISSAN CHEMICAL CORPORATION (JP) | 2026-04-30 | — | — | US | disclosed |
| EP-4142732-B1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-12522618-B2 | Copper complexes for treatment of neurodegenerative disorders | ALS THERAPY DEVELOPMENT INSTITUTE (US) | 2026-01-13 | — | — | US | disclosed |
| EP-4314945-B1 | ELECTROCHROMIC ELEMENT, ELECTROCHROMIC DISPLAY DEVICE, ELECTROCHROMIC LIGHT-CONTROLLING DEVICE, AND ELECTROLYTE COMPOSITION | RICOH CO LTD (JP) | 2025-12-17 | — | — | EP | disclosed |
| US-20250340516-A1 | Isoquinolinones as Modulators of POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250302046-A1 | BROAD SPECTRUM DISINFECTING COMPOSITIONS | ADVANCED PEROXIDE TECHNOLOGIES (APT) B.V. (NL) | 2025-10-02 | — | — | US | disclosed |
| WO-2025202174-A1 | BROAD SPECTRUM DISINFECTING COMPOSITIONS | ADVANCED PEROXIDE TECHNOLOGIES (APT) B.V. (NL) | 2025-10-02 | — | — | WO | disclosed |
| EP-0088128-A1 | ANTIINFLAMMATORY AND ANALGETIC 4-PYRIDYLPYRIDAZIN(2H)-3-ONES | DIAMOND SHAMROCK CORPORATION (US) | 1983-09-14 | — | — | EP | disclosed |
| WO-1983000863-A1 | ANTIINFLAMMATORY AND ANALGETIC 4-PYRIDYLPYRIDAZIN(2H)-3-ONES | DIAMOND SHAMROCK CORP (US) | 1983-03-17 | — | — | WO | disclosed |
| EP-0068880-A1 | Photographic elements capable of providing oxoindolizine and oxoindolizinium dye compounds | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1983-01-05 | — | — | EP | disclosed |
| EP-0060144-A2 | Cephalosporin antibiotics | ELI LILLY AND COMPANY (US) | 1982-09-15 | — | — | EP | disclosed |
| US-4336253-A | Cephalosporin antibiotics | ELI LILLY AND COMPANY (US) | 1982-06-22 | — | — | US | disclosed |
| US-4262000-A | CONTAINING ETHER AND KETONE OR HYDROXYL GROUPS | BAYER AKTIENGESELLSCHAFT (DE) | 1981-04-14 | — | — | US | disclosed |
| US-4198504-A | ANTIBIOTIC | BRISTOL-MYERS COMPANY (US) | 1980-04-15 | — | — | US | disclosed |
| US-3993656-A | BRONCHODILATOR, HYPOTENSIVES | MERCK & CO., INC. (US) | 1976-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250302046-A1 | BROAD SPECTRUM DISINFECTING COMPOSITIONS | CAT, APOBEC3C, APOBEC3A | NAPRT 4546/4885ALDH1A1 223/4885CYP1A2 2154/4885 |
| US-20260117105-A1 | POLISHING COMPOSITION HAVING EXCELLENT STORAGE STABILITY AND METHOD FOR PRODUCING SAME | SRPRA, SEM1, PSMA1 | NAPRT 3967/4885ALDH1A1 4461/4885CYP1A2 4733/4885 |
| US-12630742-B2 | Polishing composition using polishing particles containing basic substance and having high water affinity | POLR1A, PRMT1, SRRM2 | NAPRT 2321/4885ALDH1A1 4112/4885CYP1A2 4248/4885 |
| US-20250340516-A1 | Isoquinolinones as Modulators of POLRMT | POLRMT, TFAM, UQCRC1 | NAPRT 697/4885ALDH1A1 2148/4885CYP1A2 2076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.